# Does Psilocybin Require Psychedelic Effects to Treat Depression?

> **NCT05710237** · PHASE2 · COMPLETED · sponsor: **Centre for Addiction and Mental Health** · enrollment: 41 (actual)

## Conditions studied

- Treatment-resistant Depression

## Interventions

- **DRUG:** Psilocybin 25 mg
- **DRUG:** Risperidone 1 MG
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05710237
- **Lead sponsor:** Centre for Addiction and Mental Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-01
- **Primary completion:** 2026-04-14
- **Final completion:** 2026-04-14
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05710237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05710237, "Does Psilocybin Require Psychedelic Effects to Treat Depression?". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05710237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*